Can too much vitamin d cause skin rash?

Long-term side effects Taking too much cholecalciferol over a long period of time can cause a skin rash. It can also cause high levels of calcium. Too much calcium in the body (hypercalcaemia) can cause stomach pain, weaken bones, and damage the kidneys and heart. Taking too much vitamin D can lead to excessive calcium absorption, which can lead to several potentially dangerous symptoms.

It appears that approximately 1 person out of every 300 people has an allergic-type reaction to vitamin D in a matter of days. I don't have any specific references (it's just an impression of reading more than 12,000 articles on vitamin D). The allergic reaction may include itchy skin, hives, and intestinal discomfort. Urticaria is a skin disorder commonly referred to as “hives”.

It is a skin rash characterized by pale red, raised, and itchy bumps, which can also cause a burning sensation or stinging. There are several classifications of urticaria depending on the form in which it occurs, as well as the duration of the eruptions. In simple terms, urticaria can be divided into acute and chronic types. Fatigue, depression, muscle pain, and other symptoms of vitamin D deficiency coincide with symptoms of high arterial hypertrophy.

However, a vitamin D deficiency can also lead to redness, dryness and itching on the skin. The pathogenesis of AD is complex and multifactorial, and involves abnormalities in the cells of the immune system and the skin barrier. Keep in mind that people with low or deficient levels of vitamin D may need to take levels much higher than the safe maximum limit to achieve and maintain optimal levels of vitamin D. In addition, vitamin D can be produced endogenously when ultraviolet (UV) rays from the sun reach the skin and trigger the synthesis of vitamin D.

The clinical evaluation, which included skin erythema using a chromometer and thickness measurements with a double gauge, was carried out on days 2, 3, 4 and 7.Secondary clinical results were collected using Pro-Diary wristband devices, leading participants to participatively evaluate skin irritation, pain, and itchy skin twice a day during the 8-week trial. Due to altered VDR expression in GCT carriers, epidermal barrier function and local skin immunity could be compromised, increasing the likelihood of skin infections and subsequent exacerbations of AD. Interestingly, the inflammatory molecular differences between the intervention groups did not translate into clinically significant differences in skin redness, edema, or histology at any time (Figure 2F). Native skin cells, including sebocytes, epithelial cells, endothelial cells, fibroblasts, and melanocytes, were more enriched in light tissue samples. Diewald says that, as with the other symptoms above, the rash is most likely due to taking too many vitamin D supplements.

Skin thickness and redness were measured at the same time points as above, with the addition of a 6-week follow-up point. The quantified difference in redness between skin exposed and non-exposed to NM was significantly greater in participants with severe P-I than in participants with mild P-I at all times measured (Figure 3F). The skin reaction was fully monitored using clinical measurements, serum studies and skin tissue analysis collected in 14 visits over 8 weeks, allowing compatible multipoint comparisons to be made. Oral supplementation would prevent the risks of potentially harmful ultraviolet (UV) radiation, including skin cancer. NIH and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS; grants U01AR064144, U01AR071168, P30 AR075049, U54 AR079795 and P30 AR039750 (CWRU)).

The participants were given Pro-Diary wristband devices, which led them to record skin irritation, pain and itching in a participatory manner twice a day during both phases of the study.